Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain GABA Levels and Escitalopram in MDD
NCT00464711Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Escitalopram oxalate oral solution in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoint: Response and Remitter Status at Endpoint, Based on Change in Depression Severity Rating Scores at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00464711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00464711.